CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 13 enrolled
Drug / intervention
Maravirocdrug
Likely dose
Maraviroc 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00982878
NCT00982878Phase 1Completed
CompareCT.gov

The Penetration of Maraviroc Into the Central Nervous System in HIV-1 Infected Subjects on Stable Antiretroviral Therapy; a Phase I Pharmacokinetic Study

Imperial College London·interventional·Posted Sep 23, 2009·Updated Nov 4, 2019

In Brief

A Phase 1 clinical trial evaluating Maraviroc for HIV Infections. Completed, enrolled 13 participants across 1 site.

Detailed Summary

The purpose of this study is to describe the Central Nervous System exposure of maraviroc in HIV-1 infected subjects receiving a stable antiretroviral regimen, including maraviroc, at steady state.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited Kingdom
CollaboratorsPfizer

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 23, 2009
Enrollment StartSep 1, 2009
Primary CompletionJul 1, 2010
Study CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 16.8 years ago

Interventions

Maravirocdrug

150mg twice daily